VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 78 filers reported holding VAXCYTE INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $469,883 | +23.9% | 9,217 | +21.4% | 0.02% | +35.7% |
| Q2 2023 | $379,144 | +76.3% | 7,592 | +32.3% | 0.01% | +55.6% |
| Q1 2023 | $215,098 | -16.7% | 5,739 | 0.0% | 0.01% | -10.0% |
| Q4 2022 | $258,255 | +174.7% | 5,739 | +45.2% | 0.01% | +150.0% |
| Q3 2022 | $94,000 | +9.3% | 3,953 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $86,000 | +14.7% | 3,953 | +26.8% | 0.00% | +33.3% |
| Q1 2022 | $75,000 | +1.4% | 3,117 | 0.0% | 0.00% | +50.0% |
| Q4 2021 | $74,000 | -6.3% | 3,117 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $79,000 | +12.9% | 3,117 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $70,000 | +48.9% | 3,117 | +32.3% | 0.00% | +50.0% |
| Q1 2021 | $47,000 | +14.6% | 2,356 | +51.8% | 0.00% | 0.0% |
| Q4 2020 | $41,000 | -46.8% | 1,552 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $77,000 | – | 1,552 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |